Biannual report of the Cochrane Haematological Malignancies Group.
Trelle
Sven
S
Cochrane Haematological Malignancies Group, Cologne, Germany. sven.trelle@medizin.uni-koeln.de
Higgins
Gail
G
Kober
Thilo
T
Engert
Andreas
A
D002985:Clinical Protocols; D005060:Europe; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D015337:Multicenter Studies as Topic; D009101:Multiple Myeloma / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D012196:Review Literature as Topic; D018401:Sample Size; D033581:Stem Cell Transplantation